Abdulaziz A Bamhraz
Biographic Data
| ID | 8266786 |
|---|---|
| NAME | Abdulaziz A Bamhraz |
| GIVEN NAMES | Abdulaziz A |
| FAMILY NAME | Bamhraz |
| SIGNATURE | BAMHRAZ A A |
| AFFILIATIONS | McMaster University |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
The discontinuation of eculizumab in patients with aHUS is not without risk; it can result in HUS recurrence. Eculizumab discontinuation can be performed with close monitoring of the patients. It is essential to assess risk the factors for relapse before eculizumab discontinuation, in particular in children with a positive complement variant and any degree of residual CKD, as HUS relapse may lead to additional loss of kidney function. Resuming ec…
No prominent works on this page.
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
The discontinuation of eculizumab in patients with aHUS is not without risk; it can result in HUS recurrence. Eculizumab discontinuation can be performed with close monitoring of the patients. It is essential to assess risk the factors for relapse before eculizumab discontinuation, in particular in children with a positive complement variant and any degree of residual CKD, as HUS relapse may lead to additional loss of kidney function. Resuming ec…
Adenosine and Purinergic Signaling (1 work) · Antibody (1 work) · Atypical hemolytic uremic syndrome (1 work) · Complement system (1 work) · Complement system in diseases (1 work) · Dialysis (1 work) · Discontinuation (1 work) · Disease (1 work) · Eculizumab (1 work) · Immunology (1 work)